VYNE Therapeutics
VYNE
32 hedge funds and large institutions have $16.1M invested in VYNE Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.66% less ownership
Funds ownership: 55.57% → 54.91% (-0.66%)
30% less capital invested
Capital invested by funds: $22.9M → $16.1M (-$6.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$950K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$932K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$152K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$74.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$876K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$426K |
| 3 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$335K |
| 4 |
EAM
Exome Asset Management
New York
|
-$155K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$73.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $3.54K | -$172 | -69 | -4% |
|
|
MLA
27
MB, Levis & Associates
Center Valley,
Pennsylvania
| $2.05K | – | – | – |
|
|
CA
28
Centerpoint Advisors
Needham,
Massachusetts
| $1K | +$873 | +350 | New |
|
29
Russell Investments Group
London,
United Kingdom
| $368 | – | – | – |
|
30
JP Morgan Chase
New York
| $347 | +$17 | +7 | +4% |
|
31
Wells Fargo
San Francisco,
California
| $128 | -$272 | -109 | -63% |
|
|
ATPW
32
Ashton Thomas Private Wealth
Scottsdale,
Arizona
| $37 | +$47 | +19 | New |
|
|
VF
33
Virtu Financial
New York
| – | -$50K | -16,199 | Closed |
|
34
Millennium Management
New York
| – | -$33.7K | -10,990 | Closed |
|
|
CPG
35
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$6 | -2 | Closed |
|
VYNE Hedge Fund Activity: Q2 2024 in Review
32 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2024, worth a combined $16.1M — down 30% from $22.9M a quarter earlier.
Fund positioning in VYNE was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 9 trimmed.
The largest buyer was Silverarc Capital Management, adding an estimated $950K. The largest seller was Parkman Healthcare Partners, cutting an estimated $876K.
- 32 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $16.1M of VYNE Therapeutics stock for Q2 2024, down 30% quarter-over-quarter.
- 3 funds opened new VYNE Therapeutics positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest VYNE Therapeutics buyer in Q2 2024 was Silverarc Capital Management, an estimated $950K added.
- The largest VYNE Therapeutics seller in Q2 2024 was Parkman Healthcare Partners, an estimated $876K sold.
Based on aggregated 13F filings for Q2 2024.